Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

bone marrow. This is important because existing therapies often fail to effectively eliminate cancer cells in these tissue sites. Targeted therapy for CLL is becoming a reality, and this new approach may greatly improve the lives of patients with this disease."

The study also evaluated in vivo effects of ibrutinib using blood and tissue samples collected before and during treatment. Ibrutinib demonstrated rapid and sustained disease control in blood, lymph nodes, spleen and bone marrow. After 6 months, 95 percent of patients experienced a reduction in lymph node size and all showed reduction in spleen enlargement, with a median reduction of 55 percent. In 26 patients, for whom a bone marrow biopsy was done, tumor infiltration decreased by 82 percent.

The Progression Free Survival probability for these patients at 12 months was estimated to be 94 percent. Most adverse events were mild and manageable and included diarrhea, fatigue and rash, severe events occurred in less than 13 percent of patients. 

"We are very pleased with the continued research that is being demonstrated at AACR across 9 different presentations. These advances show the potential breadth of the ibrutinib program and provide further opportunities for us to pursue. We are grateful for the continued support of our collaborators, investigators, patients and shareholders," said Bob Duggan , CEO and chairman of the board.

Ibrutinib has been designated as a FDA Breakthrough Therapy in CLL patients with deletion 17p, based on data from completed Phase I/II clinical studies, where ibrutinib as a monotherapy was used to treat patients with this disease. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease, and may provide a substantial improvement over existing therapies for this indication.

About Chronic Lymphocytic Leukemia

CLL is the most common type of leukemia, a cancer of the whi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
(Date:8/20/2014)... Ariz. , Aug. 20, 2014   ... the  Roche  Group, today announced that its VENTANA ... CE marked in the European Union for routine ... The system, consisting of VENTANA Virtuoso software coupled ... VENTANA iScan HT slide scanner, provides automated digital ...
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 /PRNewswire-USNewswire/ ... next-generation sequencing and proteomic diagnostics and biomarker driven ... collaboration with TESARO, Inc.  Paradigm will use its ... from clinical trials to better predict which patients ... may lead to more successful clinical trial outcomes ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
(Date:8/21/2014)... Obispo, CA (PRWEB) August 21, 2014 ... of Current Pedorthics, a bi-monthly publication of the Pedorthic Footcare ... of pedorthics. , Bunion Bootie is ... alternative solution for bunion sufferers and their pain. It is ... in nearly any shoe to eliminate the friction and rubbing ...
(Date:8/21/2014)... August 21, 2014 According to a ... of Ophthalmology, environmental factors may outweigh genetics in the development ... percent of the world’s population is nearsighted, and this study ... , “This is an important finding in the field of ... only are we finding better ways to treat ophthalmological ...
(Date:8/21/2014)... Hills Medical Center of Kuwait is excited to be the ... diagnostic option for measuring tear production levels to aid in ... is a revolutionary new testing method for dry eyes. Using ... tears a patient produces and take the necessary steps to ... the Kuwait medical center. “The test collects a small amount ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Studies find that ... health. Juice cleanses offer clearer skin, more energy, refresh the ... Pearl Recovery Retreat, a wellness center in Beverly Hills, is ... from the comfort of their recovery room. , “It’s important ... them well again following surgery in our Los Angeles ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Denver ... Inspirational Sponsor for the American Lung Association in Colorado’s ... thrilled to welcome Webolutions as a sponsor,” said Curt ... Southwest, and Executive Director, American Lung Association in Colorado, ... the table in this role they’ve defined.” , Webolutions ...
Breaking Medicine News(10 mins):Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 3Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3
... as the Best in GI and Endoscopy Nursing at ... Society of Gastroenterology Nurses and Associates, Inc. (SGNA) is ... series of annual awards that recognize their dedication to ... of these four distinguished awards represent the best in ...
... Calif., May 15 ChromaDex Corporation, (OTC Bulletin ... and contract research, today announced financial results for ... calculated in accordance with U.S. Generally Accepted Accounting ... attributable to common stockholders of $0.01 per share ...
... Cimzia(R) (certolizumab pegol) now offered in an innovative ... GRIPS(R)ATLANTA, May 15 - UCB today announced that ... Necrosis Factor) approved in the U.S. for reducing ... clinical response in adult patients with moderate to ...
... it has been known that aspirin is beneficial to ... of the many different types of aspirin is likely ... led by Dr. Sean Nordt from the University of ... to a group of volunteer research subjects: regular aspirin ...
... May 15 Endocare, Inc. (Nasdaq: ENDO ... development of minimally invasive technologies used by urologists and ... results for the first quarter ended March 31, 2009. ... increase in revenue and strong margins.Total revenues for the ...
... Bruno E. Gerber is recognized in Continental Who,s ... Consultant Orthopedic Surgeon with a special interest in ... lower limbs. He also is employed as medical ... regarding innovative orthopedic laser treatment.Dr. Gerber undertook his ...
Cached Medicine News:Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 2Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 3Health News:SGNA Honors Outstanding Gastroenterology and Endoscopy Professionals With Nationwide Awards 4Health News:ChromaDex Reports 2009 Q1 Financial Results 2Health News:ChromaDex Reports 2009 Q1 Financial Results 3Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 2Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 3Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 4Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 5Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 6Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 7Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 8Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 9Health News:Cimzia(R) (certolizumab pegol) Now Available for Self-Administration in Adult Patients With Moderate to Severe Crohn's Disease 10Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Continental Who's Who Executive Press Release: Dr. Bruno E. Gerber - Medical Professional 2
... The BiPAP Pro with Bi-Flex bi-level system, ... that the BiPAP Pro takes to change ... Digital Auto-Trak Sensitivity™ which automatically triggers the ... pressures based on the patients breathing rhythm. ...
... Electrophoresis System (PGGE) is designed to ... density lipoproteins (LDL) and high density ... using nondenaturing pore gradient gel electrophoresis. ... short DNA sequencing runs. Temperature control ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Suitable for use with Leica ... bilirubinometers (pediatric) and all automated ... including Aeroset, AU Series, Cobas, ... These controls contain purified bilirubin ...
Medicine Products: